NCT07053293View on ClinicalTrials.gov

SGLT2i, Hepatic Glucose Production, and SNS

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 7, 2025

Primary Completion Date

June 1, 2027

Study Completion Date

June 30, 2027

Conditions
Type 2 Diabetes
Interventions
DRUG

Empagliflozin 25 MG

A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.

Trial Locations (1)

78229-3900

RECRUITING

Texas Diabetes Institute/UH, San Antonio

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

The University of Texas Health Science Center at San Antonio

OTHER